A Study to Compare PK, PD and Safety of UI058 and UIC202004 in Healthy Subjects
NCT ID: NCT05282914
Last Updated: 2024-07-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
41 participants
INTERVENTIONAL
2021-02-03
2021-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of UI059 and UIC202201 in Healthy Subjects
NCT06141577
A Study to Compare PK, PD and Safety of CKD-381 in Healthy Subjects
NCT03211143
A Study to Compare PK and Safety of CKD-381 and D026 in Healthy Male Subjects
NCT03444402
A Study to Compare PK, PD and Safety of the AD-214 and AD-2141
NCT05062876
A Study to Compare PK, PD and Safety of the AD-213-A and AD-2131
NCT04690868
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
UI058
administration of UI058
UI058 1Tab/day for 7days
UIC202004
administration of UIC202004
UIC202004 1Tab/day for 7days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
administration of UI058
UI058 1Tab/day for 7days
administration of UIC202004
UIC202004 1Tab/day for 7days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy subjects between the ages of 19 and 55 years at screening
* Body weight more than 50.0kg(male)/45.0kg(female)
* Body Mass Index more than 18.0kg/m2 and under 30.0kg/m2
Exclusion Criteria
* Have a gastrointestinal disease history that can effect drug absorption or surgery
* Hypersensitivity reaction or clinically significant hypersensitivity reaction in the history of investigational product
19 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Korea United Pharm. Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Min Kyu Park, Dr
Role: PRINCIPAL_INVESTIGATOR
Chungbuk National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chungbuk national university hospital
Cheongju-si, North Chungcheong, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KUP-UI058-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.